Karyopharm Therapeutics Inc. (44)

Browse by Contract Category

Contracts

Side Letter to Offer Letter, dated October 1, 2020, between the Registrant and Ran Frenkel (Filed With SEC on May 5, 2022)
Amendment #1 to Consulting Agreement, dated March 21, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
License Agreement, dated as of December 17, 2021, between the Registrant and Berlin-Chemie AG (Menarini Group) (Filed With SEC on March 1, 2022)
Amendment to Asset Purchase Agreement, dated as of July 17, 2019, by and between the Registrant and Biogen MA Inc (Filed With SEC on November 3, 2021)
Fifth Amendment to Lease, dated as of August 13, 2020, by and between the Registrant and AG-JCM Wells Avenue Property Owner, LLC (Filed With SEC on November 2, 2020)
Consulting Agreement, dated March 1, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
Severance Agreement, dated February 18, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham (Filed With SEC on March 29, 2022)
Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman (Filed With SEC on March 29, 2022)
Form of Nonstatutory Stock Option Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted January 24, 2022 (Filed With SEC on March 1, 2022)
2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
Non-Employee Director Compensation Policy, dated as of May 12, 2021 (Filed With SEC on August 5, 2021)
Omnibus Amendment to Transaction Documents, dated as of June 23, 2021, by and among the Company, Karyopharm Europe GmbH, Karyopharm Therapeutics (Bermuda) Ltd., HealthCare Royalty... (Filed With SEC on June 24, 2021)
Amended and Restated Letter Agreement, dated as of April 28, 2021, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on May 3, 2021)
Amended and Restated Letter Agreement, dated as of April 28, 2021, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on May 3, 2021)
Offer Letter, dated as of April 28, 2021, between the Company and Richard Paulson (Filed With SEC on May 3, 2021)
Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 24, 2021)
2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
Form of Restricted Stock Unit Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
Form of Option Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
Form of Nonstatutory Stock Option Agreement for Inducement Grants adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Letter Agreement, dated as of October 1, 2020, between the Registrant and Ran Frenkel (Filed With SEC on November 2, 2020)
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Consulting Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)
Transition Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on August 31, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on August 31, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Christopher B. Primiano (Filed With SEC on August 31, 2020)
Letter Agreement, dated as of August 31, 2020, between the Company and Michael Mason (Filed With SEC on August 31, 2020)
Amendment to License Agreement, dated May 1, 2020, by and between Antengene Therapeutics Limited and the Registrant (Filed With SEC on August 4, 2020)
Amendment No. 1 to the Open Market Sale Agreement, by and between the Company and Jefferies LLC, dated May 5, 2020 (Filed With SEC on May 5, 2020)
Underwriting Agreement, dated March 3, 2020, by and among the Company, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Jefferies LLC (Filed With SEC on March 4, 2020)
Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 26, 2020)
Revenue Interest Financing Agreement, dated September 14, 2019, between the Registrant and HealthCare Royalty Partners III, L.P, and HealthCare Royalty Partners IV, L.P (Filed With SEC on November 4, 2019)
Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on August 6, 2019)
Offer Letter, dated February 3, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)
Nonstatutory Stock Option Agreement, dated February 25, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)
Consulting Agreement dated January 18, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)
Retention Agreement dated January 17, 2019, between the Company and Cameron Peters (Filed With SEC on January 18, 2019)
Separation Agreement dated January 17, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)